secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105223
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA no longer considers AMT-130 Phase I/II vs external control adequate for BLA
-------------------------------------------------------------------------------

- Pre-BLA meeting feedback: FDA believes data from Phase I/II of AMT-130 vs external control may not serve as primary evidence for BLA.
- This reverses prior FDA guidance from multiple Type B meetings over past year and Breakthrough Therapy designation in April 2025.
- BLA submission timing for AMT-130 in Huntington's disease is now unclear.
- Company expects final meeting minutes within 30 days and plans to urgently engage FDA.
- uniQure also plans to pursue parallel discussions with EU and UK regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925105223/0001104659-25-105223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925105223/qure-20251103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer